This clinical trial is focused on studying metastatic colorectal cancer, which is a type of cancer that starts in the colon or rectum and spreads to the liver. The study is exploring the use of a treatment called oxaliplatin, which is a medication given as a solution for infusion, meaning it is administered directly into the bloodstream. The trial is comparing two methods of delivering oxaliplatin: one is through the veins, known as intravenous administration, and the other is directly into the arteries, known as intra-arterial administration. The study also involves additional treatments, including a combination of chemotherapy drugs called LV5FU2 and sometimes irinotecan, along with targeted therapy, which is a type of treatment that targets specific cancer cells.
The purpose of the study is to compare how well the cancer responds to these different methods of treatment. Participants will receive either the intravenous or intra-arterial administration of oxaliplatin, along with the other treatments, to see which method is more effective in controlling the cancer. The study will monitor the progression of the disease using imaging techniques and clinical evaluations to determine how long the cancer can be kept from worsening. The trial will also assess the side effects of the treatments and their impact on the participants’ quality of life.
Throughout the study, participants will undergo regular check-ups and imaging tests to track the cancer’s response to the treatment. The trial aims to provide valuable information on the best approach to treating metastatic colorectal cancer that has spread to the liver, potentially improving outcomes for patients with this condition. The study is expected to continue until 2026, allowing researchers to gather comprehensive data on the effectiveness and safety of the treatments being tested.
Belgium 
France 
